10-K: CG Oncology Reports Promising Phase 3 Data, Eyes BLA Submission in 2025

CG Oncology's 10-K filing highlights positive clinical trial results for cretostimogene, positioning the company for a potential BLA submission in the second half of 2025.

Summary

• CG Oncology, a late-stage clinical biopharmaceutical company, is focused on developing cretostimogene as a bladder-sparing therapeutic for bladder cancer.
• Cretostimogene is currently in Phase 3 clinical trials for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients unresponsive to BCG therapy.
• The company expects to initiate a Biologics License Application (BLA) submission to the FDA in the second half of 2025 based on the BOND-003 Cohort C trial.
• Topline data from the Phase 3 BOND-003 Cohort C trial showed a 74.5% complete response (CR) rate at any time, which improved to 75.5% in an updated analysis.
• Kaplan-Meier estimates for CR rate at 12 and 24 months were 50% and 41%, respectively, as of the September 30, 2024 data cutoff.
• Progression-free survival (PFS) at 12 months was 97.3%, and cystectomy-free survival at 12 months was 90.0%.
• The estimated duration of response (DoR) probability at 12 months and 24 months was 63.5% and 56.6%, respectively.
• Median DoR was not reached but exceeded 28 months as of the January 20, 2025 data cutoff.
• No Grade 3 or higher treatment-related adverse events (TRAEs) or deaths were reported in the BOND-003 trial.
• The company is also conducting other clinical trials, including BOND-003 Cohort P and CORE-008 Cohort A, with topline data expected in the second half of 2025.
• CG Oncology had 113 full-time employees as of December 31, 2024, with 42 engaged in research and development.
• The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the first half of 2028.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the promising clinical trial results and the company's plans for BLA submission. However, the risks associated with drug development and commercialization temper the overall sentiment.

Positives

• High complete response rate (75.5%) in Phase 3 trial.
• Favorable safety and tolerability profile with no Grade 3 or higher TRAEs.
• Sustained duration of response exceeding 28 months.
• Breakthrough Therapy designation from the FDA.
• Strong cash position to fund operations into the first half of 2028.
• High patient adherence and compliance, with 97.3% of patients completing all protocol-defined treatments.

Negatives

• The company has incurred significant operating losses since its inception and expects to incur significant losses for the foreseeable future.
• The company has a relatively limited operating history.
• The company currently depends entirely on the success of cretostimogene, which is our only product candidate.
• The company is in the early stages of building its internal marketing and sales organization and has no experience as a company in commercializing products.

Risks

• Reliance on the success of a single product candidate, cretostimogene.
• Uncertainty in clinical and preclinical drug development timelines and outcomes.
• Potential for adverse side effects or safety risks associated with cretostimogene.
• Dependence on third parties for clinical trials and manufacturing.
• Competition from other companies developing cancer treatments.
• Limited operating history and potential inability to generate revenue or become profitable.
• Need for substantial additional capital to finance operations.
• Potential limitations on the use of net operating loss carryforwards.
• Potential for product liability lawsuits.
• Potential for disruptions at the FDA and other government agencies.

Future Outlook

CG Oncology expects to initiate a BLA submission to the FDA in the second half of 2025 and believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the first half of 2028.

Industry Context

The bladder cancer treatment market is expected to reach $9.9 billion by 2028, highlighting the significant unmet need for alternative NMIBC therapeutics due to BCG shortages and patient aversion to cystectomy.

Comparison to Industry Standards

• The CR rate reported for valrubicin, the only approved chemotherapy for BCG-refractory NMIBC, is 18% at six months.
• In January 2020, pembrolizumab was approved by the FDA to treat high-risk BCG-unresponsive NMIBC as monotherapy based on the results of the KEYNOTE-057 Phase 2 clinical trial. In the cohort of participants with CIS-stage tumors, with or without papillary tumors, 39 of 96 patients, or 41%, had a CR at 3 months, with the median DoR being 16.2 months.
• In a Phase 3 clinical trial evaluating nadofaragene for the treatment BCG-unresponsive NMIBC, 51% of patients achieved a CR and 24% of patients maintained a CR at 12 months.
• In April 2024, nogapendekin alfa inbakicept (nogapendekin), in combination with BCG, was approved by the FDA to treat high-risk BCG-unresponsive NMIBC with CIS, with or without papillary tumors. The approval was based on a Phase 2/3 clinical trial showing 62% of BCG-unresponsive NMIBC achieved a CR and 36% of patients maintained a CR at 12 months following treatment with nogapendekin.

Legal Proceedings

• A complaint was filed against CG Oncology in the Superior Court of the State of Delaware by ANI Pharmaceuticals, Inc. seeking a declaratory judgement that an assignment and technology transfer agreement between the Company and ANI, dated November 15, 2010, obligates the Company to pay ANI a royalty on certain net sales of cretostimogene.

Stakeholder Impact

• Positive impact on patients with bladder cancer by providing a potential bladder-sparing therapeutic option.
• Potential benefits for healthcare providers through a new treatment option for BCG-unresponsive NMIBC.
• Potential returns for shareholders if cretostimogene receives regulatory approval and achieves commercial success.

Next Steps

• Initiate a BLA submission to the FDA for cretostimogene in the second half of 2025.
• Report topline data from BOND-003 Cohort P in the second half of 2025.
• Report topline data from CORE-008 Cohort A in the second half of 2025.
• Continue clinical development and commercialization preparation for cretostimogene.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, clinical trial, FDA, BOND-003, biopharmaceutical, oncology, therapy, BCG